NI200900139A - Derivados de espirocromanona sustituidos como inhibidores de acc. - Google Patents
Derivados de espirocromanona sustituidos como inhibidores de acc.Info
- Publication number
- NI200900139A NI200900139A NI200900139A NI200900139A NI200900139A NI 200900139 A NI200900139 A NI 200900139A NI 200900139 A NI200900139 A NI 200900139A NI 200900139 A NI200900139 A NI 200900139A NI 200900139 A NI200900139 A NI 200900139A
- Authority
- NI
- Nicaragua
- Prior art keywords
- group
- optionally substituted
- cycloalkyl
- alkyl
- atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
Abstract
La invención se refiere a un compuesto de fórmula general (I): (I) en la que Ar1 representa un grupo formado desde un anillo aromático seleccionado del grupo constituido por indol, 1H-indazol, 2H-indazol, 1H-tieno[2,3-c]pirazol, 1H-pirazolo[3,4-b]piridina, benzo[b]furano, benzimidazol, benzoxazol, 1,2-benzisoxazol e imidazo[1,2-a]piridina; R1 y R2 representan cada uno un átomo de hidrógeno, un átomo de halógeno, un grupo ciano, un grupo alquenilo C2-C6, un grupo alcoxi C1-C6, un grupo haloalcoxi C1-C6, un grupo cicloalquiloxi C3-C6, un grupo alcanoílo C2-C7, un grupo haloalcanoílo C2-C7, un grupo alcoxicarbonilo C2-C7, un grupo haloalcoxicarbonilo C2-C7, un grupo cicloalcoxicarbonilo C3-C6 , un grupo aralquiloxicarbonilo, un grupo carbamoilalcoxi C1-C6, un grupo carboxialquenilo C2-C6, o un grupo de -Q1-N(Ra)-Q2-Rb; un grupo alquilo C1-C6, arilo o heterocíclico opcionalmente sustituido; o un grupo alquilo C1-C6 o alquenilo C2-C6 que tienen el grupo arilo o heterocíclico; R3 y R4 representan cada uno un átomo de hidrógeno, un átomo de halógeno, un grupo nitro, un grupo cicloalquilo C3-C6, un grupo carbamoílo opcionalmente sustituido por un grupo alquilo C1-C6 o un grupo cicloalquilo C3-C6, o un grupo de -N(Re)Rf; un grupo alcanoílo C2-C7, alcoxi C1-C6, alcoxicarbonilo C2-C7, cicloalcoxicarbonilo C3-C6, alquilsulfonilo C1-C6, alquiltio C1-C6, cicloalquiloxi C3-C6, cicloalquil C3-C6- alcoxi C1-C6, cicloalquilsulfonilo C3-C6, cicloalquiltio C3-C6 o cicloalquil C3-C6- alquiltio C1-C6 opcionalmente sustituido; o un grupo alquilo C1-C6 opcionalmente sustituido; T y U representan cada uno un átomo de nitrógeno o un grupo metino; y V representa un átomo de oxígeno o un átomo de azufre. El compuesto de la invención es útil como agente terapéutico para diversas enfermedades relacionadas con la ACC.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88030207P | 2007-01-12 | 2007-01-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI200900139A true NI200900139A (es) | 2010-02-24 |
Family
ID=39297859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI200900139A NI200900139A (es) | 2007-01-12 | 2009-07-08 | Derivados de espirocromanona sustituidos como inhibidores de acc. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8093389B2 (es) |
| EP (1) | EP2111406B1 (es) |
| JP (1) | JP5319550B2 (es) |
| KR (1) | KR20090108022A (es) |
| CN (1) | CN101631791B (es) |
| AR (1) | AR064824A1 (es) |
| AU (1) | AU2008205638B2 (es) |
| BR (1) | BRPI0806531A2 (es) |
| CA (1) | CA2674573C (es) |
| CL (1) | CL2008000067A1 (es) |
| CO (1) | CO6190611A2 (es) |
| CR (1) | CR10944A (es) |
| DO (1) | DOP2009000176A (es) |
| EC (1) | ECSP099503A (es) |
| GT (1) | GT200900194A (es) |
| HK (1) | HK1131136A1 (es) |
| HN (1) | HN2009001276A (es) |
| MA (1) | MA31108B1 (es) |
| MX (1) | MX2009007502A (es) |
| NI (1) | NI200900139A (es) |
| NZ (1) | NZ577825A (es) |
| PE (1) | PE20081559A1 (es) |
| RU (1) | RU2009130736A (es) |
| SG (1) | SG177977A1 (es) |
| TW (1) | TW200836727A (es) |
| UA (1) | UA103990C2 (es) |
| WO (2) | WO2008088689A1 (es) |
| ZA (1) | ZA200904138B (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE509023T1 (de) * | 2005-07-19 | 2011-05-15 | Merck Sharp & Dohme | Spirochromanon-derivate als acetyl-koenzym-a- carboxylase-hemmer |
| US8138197B2 (en) * | 2007-01-12 | 2012-03-20 | Msd K.K. | Spirochromanon derivatives |
| EP2242745A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| US8524730B2 (en) * | 2008-07-04 | 2013-09-03 | Msd K.K. | Spirochromanone carboxylic acids |
| EP2310015A4 (en) * | 2008-07-14 | 2011-10-26 | Cropsolution Inc | ACETYL-COENZYME-CARBOXYLASE MODULATORS AND METHODS OF USE THEREOF |
| WO2010059788A1 (en) | 2008-11-20 | 2010-05-27 | Genentech, Inc. | Pyrazolopyridine pi3k inhibitor compounds and methods of use |
| CA2778886C (en) | 2009-11-10 | 2014-01-07 | Pfizer Inc. | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| JP5820391B2 (ja) * | 2009-12-31 | 2015-11-24 | デカ・プロダクツ・リミテッド・パートナーシップ | 注入ポンプアセンブリ |
| EP2595989B1 (en) | 2010-05-06 | 2016-07-13 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| CN101851237B (zh) * | 2010-06-18 | 2012-10-17 | 南方医科大学 | 一种螺环化合物及其制备方法和应用 |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| PT2621493T (pt) | 2010-09-30 | 2016-11-14 | Pfizer | Inibidores de n1-pirazolospirocetona acetil-coa carboxilase |
| RU2540337C2 (ru) | 2010-10-29 | 2015-02-10 | Пфайзер Инк. | N1/N2-ЛАКТАМНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ |
| WO2012077655A1 (ja) * | 2010-12-07 | 2012-06-14 | 塩野義製薬株式会社 | Ｇｐｒ１１９アゴニスト活性を有するスピロ誘導体 |
| TWI520964B (zh) | 2011-02-02 | 2016-02-11 | 維泰克斯製藥公司 | 作為離子通道調節劑之吡咯并吡－螺環哌啶醯胺 |
| WO2012112743A1 (en) | 2011-02-18 | 2012-08-23 | Vertex Pharmaceuticals Incorporated | Chroman - spirocyclic piperidine amides as modulators of ion channels |
| EP2686325B1 (en) | 2011-03-14 | 2016-12-14 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| SI2699576T1 (sl) | 2011-04-22 | 2016-02-29 | Pfizer Inc. | Derivati pirazolospiroketonov za uporabo kot zaviralci acetil-CoA karboksilaze |
| JPWO2012161119A1 (ja) * | 2011-05-20 | 2014-07-31 | 興和株式会社 | 新規なスピロピペリジン誘導体及びこれを含有する医薬 |
| WO2013113716A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| JP2015511940A (ja) | 2012-02-03 | 2015-04-23 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | 殺菌性ピリミジン化合物 |
| WO2013113776A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113787A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| WO2013113773A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| CN104220428A (zh) | 2012-02-03 | 2014-12-17 | 巴斯夫欧洲公司 | 杀真菌嘧啶化合物 |
| WO2013113720A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| EP2970177A1 (en) | 2013-03-15 | 2016-01-20 | Pfizer Inc. | Indole compounds that activate ampk |
| CN105358155A (zh) | 2013-05-10 | 2016-02-24 | 尼普斯阿波罗有限公司 | Acc抑制剂和其用途 |
| AU2014262638A1 (en) | 2013-05-10 | 2015-11-26 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
| CN105530940A (zh) | 2013-09-12 | 2016-04-27 | 辉瑞大药厂 | 乙酰辅酶a羧化酶抑制剂用于治疗寻常痤疮的用途 |
| US11046707B2 (en) | 2016-12-14 | 2021-06-29 | 89Bio Ltd | Spiropiperidine derivatives |
| MX2019015849A (es) * | 2017-06-30 | 2020-08-03 | Quixgen Inc | Nuevos compuestos de espirolactona. |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2814983A1 (de) * | 1978-04-07 | 1979-10-18 | Bayer Ag | Neue chromanon-derivate |
| JPH03182725A (ja) | 1989-12-08 | 1991-08-08 | Internatl Business Mach Corp <Ibm> | 非線形光学素子及びその製造方法 |
| IL96507A0 (en) | 1989-12-08 | 1991-08-16 | Merck & Co Inc | Nitrogen-containing spirocycles and pharmaceutical compositions containing them |
| US5206240A (en) * | 1989-12-08 | 1993-04-27 | Merck & Co., Inc. | Nitrogen-containing spirocycles |
| NZ243065A (en) | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| ATE169001T1 (de) | 1993-01-28 | 1998-08-15 | Merck & Co Inc | Substituierte spiro-azaringen als tachykinine rezeptor antagonisten |
| US6017768A (en) | 1994-05-06 | 2000-01-25 | Pharmacopeia, Inc. | Combinatorial dihydrobenzopyran library |
| US5856083A (en) | 1994-05-06 | 1999-01-05 | Pharmacopeia, Inc. | Lawn assay for compounds that affect enzyme activity or bind to target molecules |
| WO1995030642A1 (en) | 1994-05-06 | 1995-11-16 | Pharmacopeia, Inc. | Combinatorial dihydrobenzopyran library |
| US5688997A (en) * | 1994-05-06 | 1997-11-18 | Pharmacopeia, Inc. | Process for preparing intermediates for a combinatorial dihydrobenzopyran library |
| AU705661B2 (en) | 1995-06-06 | 1999-05-27 | Merck & Co., Inc. | Alpha 1a adrenergic receptor antagonists |
| GB9601724D0 (en) * | 1996-01-29 | 1996-03-27 | Merck Sharp & Dohme | Therapeutic agents |
| GB0003397D0 (en) * | 2000-02-14 | 2000-04-05 | Merck Sharp & Dohme | Therapeutic agents |
| WO2002020509A2 (de) | 2000-09-06 | 2002-03-14 | Bayer Aktiengesellschaft | Arzneimittel gegen virale erkrankungen |
| JP2005162612A (ja) | 2002-01-09 | 2005-06-23 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| JP2005170790A (ja) | 2002-01-09 | 2005-06-30 | Ajinomoto Co Inc | Ｎ−アルキルスルフォニル置換アミド誘導体 |
| EA200400980A1 (ru) | 2002-02-27 | 2005-02-24 | Пфайзер Продактс Инк. | Ингибиторы асс |
| JP2005320250A (ja) | 2002-05-09 | 2005-11-17 | Ajinomoto Co Inc | ビスラクトン誘導体及びその医薬組成物としての使用 |
| AU2003299791A1 (en) | 2002-12-20 | 2004-07-22 | Bayer Pharmaceuticals Corporation | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity |
| JPWO2004092179A1 (ja) | 2003-04-14 | 2006-07-06 | 日本曹達株式会社 | スピロ誘導体、製造法および抗酸化薬 |
| FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
| JP2005119987A (ja) | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| US8138342B2 (en) | 2004-10-12 | 2012-03-20 | High Point Pharmacueticals, LLC | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds |
| JP2008520700A (ja) | 2004-11-18 | 2008-06-19 | インサイト・コーポレイション | １１−βヒドロキシルステロイドデヒドロゲナーゼタイプＩの阻害剤およびその使用方法 |
| WO2006117669A1 (en) * | 2005-05-03 | 2006-11-09 | Pfizer Inc. | Amide resorcinol compounds |
| ATE509023T1 (de) * | 2005-07-19 | 2011-05-15 | Merck Sharp & Dohme | Spirochromanon-derivate als acetyl-koenzym-a- carboxylase-hemmer |
| CA2670422C (en) | 2006-11-29 | 2011-09-06 | Pfizer Products Inc. | Spiroketone acetyl-coa carboxylase inhibitors |
| US8138197B2 (en) * | 2007-01-12 | 2012-03-20 | Msd K.K. | Spirochromanon derivatives |
-
2008
- 2008-01-04 PE PE2008000089A patent/PE20081559A1/es not_active Application Discontinuation
- 2008-01-07 TW TW097100608A patent/TW200836727A/zh unknown
- 2008-01-08 KR KR1020097014377A patent/KR20090108022A/ko not_active Application Discontinuation
- 2008-01-08 UA UAA200908468A patent/UA103990C2/ru unknown
- 2008-01-08 AU AU2008205638A patent/AU2008205638B2/en not_active Ceased
- 2008-01-08 SG SG2012002739A patent/SG177977A1/en unknown
- 2008-01-08 BR BRPI0806531-4A2A patent/BRPI0806531A2/pt not_active IP Right Cessation
- 2008-01-08 EP EP08713050A patent/EP2111406B1/en active Active
- 2008-01-08 WO PCT/US2008/000223 patent/WO2008088689A1/en active Application Filing
- 2008-01-08 US US12/007,000 patent/US8093389B2/en active Active
- 2008-01-08 JP JP2009545577A patent/JP5319550B2/ja not_active Expired - Fee Related
- 2008-01-08 MX MX2009007502A patent/MX2009007502A/es unknown
- 2008-01-08 WO PCT/US2008/000221 patent/WO2008088688A1/en active Application Filing
- 2008-01-08 CN CN2008800021443A patent/CN101631791B/zh not_active Expired - Fee Related
- 2008-01-08 NZ NZ577825A patent/NZ577825A/en not_active IP Right Cessation
- 2008-01-08 RU RU2009130736/04A patent/RU2009130736A/ru not_active Application Discontinuation
- 2008-01-08 CA CA2674573A patent/CA2674573C/en not_active Expired - Fee Related
- 2008-01-09 AR ARP080100081A patent/AR064824A1/es not_active Application Discontinuation
- 2008-01-10 CL CL200800067A patent/CL2008000067A1/es unknown
-
2009
- 2009-06-12 ZA ZA200904138A patent/ZA200904138B/xx unknown
- 2009-07-06 HN HN2009001276A patent/HN2009001276A/es unknown
- 2009-07-06 GT GT200900194A patent/GT200900194A/es unknown
- 2009-07-08 NI NI200900139A patent/NI200900139A/es unknown
- 2009-07-09 DO DO2009000176A patent/DOP2009000176A/es unknown
- 2009-07-09 EC EC2009009503A patent/ECSP099503A/es unknown
- 2009-07-13 CO CO09072490A patent/CO6190611A2/es active IP Right Grant
- 2009-07-20 CR CR10944A patent/CR10944A/es unknown
- 2009-07-23 MA MA32114A patent/MA31108B1/fr unknown
- 2009-11-13 HK HK09110661.8A patent/HK1131136A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI200900139A (es) | Derivados de espirocromanona sustituidos como inhibidores de acc. | |
| WO2008088692A3 (en) | Spirochromanon derivatives | |
| AR114667A2 (es) | Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina | |
| PE20081836A1 (es) | Derivados de piperidina como inhibidores de la sintasa de acido graso | |
| NZ748072A (en) | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators | |
| PE20030200A1 (es) | Bencimidazol como inhibidores de las map quinasas | |
| NO20080717L (no) | Oksimderivat og fremgangsmate for fremstilling av dette | |
| AR076170A1 (es) | Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden. | |
| PE20040835A1 (es) | Administracion combinada de una indolina con un agente quimioterapeutico para transtornos de proliferacion celular | |
| ATE443701T1 (de) | Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion | |
| AR087196A1 (es) | Metodos plaguicidas que utilizan compuestos de 3-piridil tiazol sustituido y derivados para combatir las plagas de animales ii | |
| AR058719A1 (es) | Derivados de isoxazol-4-il-oxadiazol | |
| AR040726A1 (es) | Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento | |
| PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
| NO20063475L (no) | Nye 2-heteroarylsubstituerte benzimidazolderivater | |
| CO6220935A2 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 | |
| PE20120764A1 (es) | Derivados de isotiazolo-pirimidindiona como moduladores de trpa1 | |
| PE20121047A1 (es) | Derivados de tiazolilpiperidina como fungicidas | |
| PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
| AR046222A1 (es) | Composiciones farmaceuticas de liberacion sostenida que incluyen aplindore y sus derivados | |
| PE20120900A1 (es) | Compuestos heterociclicos de fenoximetilo | |
| CO5700763A2 (es) | Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra | |
| PE20071225A1 (es) | Compuestos derivados de piperidina como inhibidores de neurocinina-1 (nk-1) y del transportador de serotonina | |
| CO5611121A2 (es) | Derivados de fenil amidas con silicio utiles como microbicidas | |
| AR083861A1 (es) | OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN |